HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion

This is a Phase Ib, open-label, multicenter study of HSK41959 tablets in combination with standard therapy in patients with MTAP-deficient advanced solid tumors. The study consists of dose-escalation and dose-expansion parts and is intended to evaluate the safety, tolerability, dose-limiting toxicity, maximum tolerated dose, pharmacokinetics, pharmacodynamics, and preliminary efficacy of HSK41959 tablets when used together with standard therapy.

NCT Number	NCT07699757
Lead Sponsor	Haisco Pharmaceutical Group Co., Ltd.
Conditions	Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors
Enrollment	258 participants
Start Date	2026-07
Primary Completion	2029-04 (estimated)
Study Completion	2029-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-14